TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01379144
Drug: latanoprost 100 ug
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study: NCT01379144
Drug: latanoprost 125 ug
Normalized name: latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study: NCT01902992
Drug: Depiquick Birch (DPG103)
Normalized name: BIRCH TRITERPENES
DrugBank: Birch bark extract (DB16536)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01379144
Drug: latanoprost 50 ug
Normalized name: LATANOPROST 50 ug in 1 mL OPHTHALMIC SOLUTION
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study: NCT01702493
Drug: Tab SRT2104 fast release
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New 250 mg SRT2104 mesylate salt fast release tablet
Study: NCT02368561
Drug: Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)
Normalized name: Synvisc Injectable Product
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
Study: NCT02711241
Drug: Dipyrone
Normalized name: Dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram by slow IV infusion
Study: NCT02711241
Drug: Papaverine
Normalized name: Papaverine
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg by slow intravenous infusion
Study: NCT00120757
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04267601
Drug: Anagliptin
Normalized name: Anagliptin
DrugBank: Anagliptin (DB12417)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anagliptin treatment for 24weeks
Study: NCT02019485
Drug: Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)
Normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
Study: NCT02019485
Drug: Tapentadol Prolonged-Release Formulation 2 (PR2)
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
Study: NCT02238067
Drug: ESA
Normalized name: GenESA
DrugBank: Arbutamine (DB01102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
Study: NCT01864005
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
Study: NCT01864005
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
Study: NCT03162367
Drug: Silver sulfadiazine ointment
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
Study: NCT04216134
Drug: Gallium Ga 68-labeled PSMA-11
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004368
Drug: colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01719744
Drug: ENMD-2076
Normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01433289
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
Study: NCT03084783
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
Study: NCT03781817
Drug: Intravenous Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
Study: NCT03781817
Drug: Intranasal Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
Study: NCT01564810
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
Study: NCT01564810
Drug: chemotherapy of mFOLFOX6 or FOLFIRI
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
Study: NCT03541395
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04509622
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; Oral
Study: NCT04509622
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous Injection
Study: NCT00443963
Drug: Esomeprazole Magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PPI compared to H2RA
Study: NCT03021993
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
Study: NCT00686114
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.
Study: NCT00686114
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
Study: NCT00686114
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
Study: NCT03554486
Drug: Fiasp
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
Study: NCT03554486
Drug: Novolog
Normalized name: NovoLog
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
Study: NCT03867318
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin administered orally QD as 10 mg tablets.
Study: NCT03867318
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe administered orally QD as 10 mg tablets
Study: NCT03867318
Drug: Placebo for Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single placebo tablet administered orally QD
Study: NCT03867318
Drug: Placebo for Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single placebo tablet administered orally QD
Study: NCT02640508
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
Study: NCT02640508
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be taken orally at 20-24 mg daily in each 21 day cycle.
Study: NCT01383343
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01383343
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00010452
Drug: picibanil
Normalized name: Picibanil
DrugBank: Picibanil (DB17591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to .2 mg per injection, given intralesionally every 6-8 weeks
Study: NCT04343235
Drug: furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: five day course of furosemide 20mg QD
Study: NCT04343235
Drug: labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg labetalol BID
Study: NCT01763996
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat capsules
Study: NCT01763996
Drug: Febuxostat placebo
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat placebo-matching capsules
Study: NCT02219867
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug (including placebo)
Study: NCT03739021
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
Study: NCT03739021
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
Study: NCT01065246
Drug: catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
Study: NCT00466570
Drug: gatifloxacin, moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01284413
Drug: S-1, Gemcitabine, Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
Study: NCT00132548
Drug: Pyrimethamine/sulfadoxine
Normalized name: PYRIMETHAMINE/SULFADOXINE
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00132548
Drug: Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00132548
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00452361
Drug: Sirolimus+MMF or MPS or AZA+Steroid
Normalized name: Medicated Pad or Tape
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
Study: NCT03251443
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study: NCT00512980
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00512980
Drug: vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00512980
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00776919
Drug: BPO gel
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day application to the face
Study: NCT02371941
Drug: oral cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cromolyn sodium
Study: NCT02129088
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
Study: NCT03116152
Drug: paclitaxel/ irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
Study: NCT01966718
Drug: Repository corticotropin injection
Normalized name: Repository Corticotropin Injection
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
Study: NCT00665808
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany
Study: NCT00862641
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT00420043
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03334786
Drug: FLX-787-ODT
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Disintegrating Tablet
Study: NCT03179605
Drug: DFD06
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apply twice per day for 15 days
Study: NCT01284036
Drug: PF-05230905
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
Study: NCT06517485
Drug: upifitamab rilsodotin
Normalized name: Upinitatug rilsodotin
DrugBank: Upinitatug rilsodotin (DB19104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study: NCT01715441
Drug: Sorafenib and irinotecan combination
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01715441
Drug: Sorafenib monotherapy
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01715441
Drug: Irinotecan monotherapy
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06244290
Drug: Colgate SNF
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: toothpaste
Study: NCT06244290
Drug: Sensodyne Extra Whitening
Normalized name: Sensodyne Extra Whitening Toothpaste
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: toothpaste
Study: NCT06244290
Drug: Colgate Fluoride (CDC)
Normalized name: sodium fluoride Mouthwash [Colgate]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: toothpaste
Study: NCT02867384
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: B cell depletion
Study: NCT02230917
Drug: Sotatercept
Normalized name: Sotatercept
DrugBank: Sotatercept (DB12118)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02141737
Drug: Lidocaine Hydrochloride Injection
Normalized name: Lidocaine Hydrochloride Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
Study: NCT02141737
Drug: Etomidate Fat Emulsion Injection
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
Study: NCT02141737
Drug: Midazolam Injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
Study: NCT02141737
Drug: Rocuronium Injection
Normalized name: rocuronium Injectable Solution
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
Study: NCT01410916
Drug: Eculizumab (Soliris®)
Normalized name: eculizumab Injection [Soliris]
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
Study: NCT04499313
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injectable solution
Study: NCT04499313
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injectable solution
Study: NCT01217307
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg twice daily during 4 months
Study: NCT00094484
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04136015
Drug: Dasatinib 100 MG
Normalized name: dasatinib 100 MG
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
Study: NCT01258322
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
Study: NCT00761761
Drug: Sensoril
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03283605
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
Study: NCT03283605
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.